Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00702923 · ClinicalTrials.gov registry record · Phase 1
CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer
A Phase 1 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00702923: Clinical Trial Phase 1 study, sponsored by University of Wisconsin, Madison.
NCT00702923 is a Phase 1 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 12 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00702923, a Phase 1 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The current protocol will evaluate the safety of combining treatment with bicalutamide(Casodex) and CP-675,206 (anti-CTLA-4 monoclonal antibody) in patients with PSA-recurrent non-metastatic (stage D0) prostate cancer. This is a dose escalation study with safety the primary endpoint. Secondary endpoints will be to determine whether prostate associated immune responses are seen, and whether treatment is associated with an increase in PSA doubling time and PSA recurrence at one year, as markers of clinical activity. Cohorts of six patients will be treated in each dose level. The investigators hypothesize that short-term androgen deprivation therapy will elicit prostate cancer-associated T-cell mediated tissue destruction that can be augmented with a monoclonal antibody blocking CTLA-4, and that this will have therapeutic benefit in patients with recurrent prostate cancer.
Interventions
- DRUG Bicalutamide and CP-675,206 (Tremelimumab)
- DRUG Bicalutamide, CP-675,206 (tremelimumab)
- DRUG Bicalutamide, CP-675,206 (Tremelimumab)
- DRUG Bicalutamide, CP-675,206
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2008-07 |
| Est. Completion | 2013-03 |
| Phase | Phase 1 |
Why NCT00702923 stopped before completion
NCT00702923 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (80% lower).
The record links to 0 conditions, and to 4 interventions - of which Bicalutamide and CP-675,206 (Tremelimumab) is the first listed.
NCT00702923 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00702923 about?
NCT00702923 is a clinical study titled "CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer". The current protocol will evaluate the safety of combining treatment with bicalutamide(Casodex) and CP-675,206 (anti-CTLA-4 monoclonal antibody) in patients with PSA-recurrent non-metastatic (stage D0) prostate cancer. This is a dose escalation study with safety the primary endpoint. Secondary endpo...
What is the current status of trial NCT00702923?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2008-07. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00702923?
The interventions under investigation include: Bicalutamide and CP-675,206 (Tremelimumab) (DRUG), Bicalutamide, CP-675,206 (tremelimumab) (DRUG), Bicalutamide, CP-675,206 (Tremelimumab) (DRUG), Bicalutamide, CP-675,206 (DRUG).
Who is sponsoring clinical trial NCT00702923?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00702923's enrollment target sits among peer trials
12 1852nd of 2000 higher than 90 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia